WO2023021363 - SYNTHESIS OF BRIVARACETAM
National phase entry:
Publication Number
WO/2023/021363
Publication Date
23.02.2023
International Application No.
PCT/IB2022/057344
International Filing Date
06.08.2022
Title **
[English]
SYNTHESIS OF BRIVARACETAM
[French]
SYNTHÈSE DE BRIVARACÉTAM
Applicants **
OPTIMUS DRUGS PRIVATE LIMITED
Inventors
SRINIVASA REDDY, Desireddy
SUBBA REDDY, Peketi
MADHAVA REDDY, Vedururi
Priority Data
202141037050
16.08.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 11551 | |
| Japan | Filing, Examination, Granting | 1907 | |
| South Korea | Filing, Examination, Granting | 1603 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
22,959
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a novel compound of (S)-2-((Z)-((R)-4-propyldihydrofuran-2(3H)-ylidene) amino) butanamide and an improved, commercially viable process for preparation of Brivaracetam using (S)-2-((Z)-((R)-4-propyldihydrofuran-2(3H)-ylidene) amino) butanamide.[French]
La présente invention concerne un nouveau composé de (S)-2-((Z)-((R)-4-propyldihydrofuran-2(3H)-ylidène) amino) butanamide et un procédé amélioré, commercialement viable pour la préparation de brivaracétam à l'aide de (S)-2-((Z)-((R)-4-propyldihydrofuran-2(3H)-ylidène) amino) butanamide.